NASDAQ:DVAX - Dynavax Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.70 -0.40 (-2.34 %)
(As of 05/21/2018 02:54 PM ET)
Previous Close$17.25
Today's Range$16.67 - $17.25
52-Week Range$5.35 - $24.45
Volume46,585 shs
Average Volume1.63 million shs
Market Capitalization$1.06 billion
P/E Ratio-9.65
Dividend YieldN/A
Beta0.86

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies logoDynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for oncology. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for various immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.

Receive DVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:DVAX
CUSIP26815810
Phone510-848-5100

Debt

Debt-to-Equity Ratio0.60
Current Ratio10.85
Quick Ratio10.83

Price-To-Earnings

Trailing P/E Ratio-9.65
Forward P/E Ratio-7.95
P/E GrowthN/A

Sales & Book Value

Annual Sales$330,000.00
Price / Sales3,151.24
Cash FlowN/A
Price / CashN/A
Book Value$3.29 per share
Price / Book5.08

Profitability

EPS (Most Recent Fiscal Year)($1.73)
Net Income$-95,150,000.00
Net Margins-31,635.17%
Return on Equity-60.61%
Return on Assets-48.71%

Miscellaneous

Employees170
Outstanding Shares62,270,000

Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies (NASDAQ:DVAX) posted its earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.14. The biopharmaceutical company earned $0.17 million during the quarter, compared to analyst estimates of $0.82 million. Dynavax Technologies had a negative return on equity of 60.61% and a negative net margin of 31,635.17%. The firm's revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.60) earnings per share. View Dynavax Technologies' Earnings History.

When is Dynavax Technologies' next earnings date?

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Dynavax Technologies.

What price target have analysts set for DVAX?

5 equities research analysts have issued twelve-month price objectives for Dynavax Technologies' stock. Their predictions range from $25.00 to $30.00. On average, they expect Dynavax Technologies' share price to reach $27.40 in the next twelve months. View Analyst Ratings for Dynavax Technologies.

What are Wall Street analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:
  • 1. Cantor Fitzgerald analysts commented, "HEPLISAV-B Launched. Dynavax reported that HEPLISAV-B, a two-dose hepatitis B vaccine, has been launched in the U.S. with a 60-person field sales team covering 75% of the market. HEPLISAV-B was recommended by the CDC for use in the vaccination of adults, which the company believes is critical to drive broad insurance coverage and adoption. By now, 100% of Medicare lives, 74% of commercially-insured lives, and 60% of lives covered under Medicaid plans have HEPLISAV-B specific CPT codes, referencing the correct price. In the first two months following launch, the sales team met two-thirds of the targeted key accounts, corresponding to more than half of the addressable market. The sales cycle is estimated to be 6-8 weeks at this stage. As previously reported, the company has a drug supply of over 250,000 vials, with an additional 750,000 vials worth of raw material." (5/8/2018)
  • 2. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (1/10/2018)
  • 3. Cowen Inc analysts commented, "Dynavax reported a Q3 net loss of $22.1MM and ended the quarter with $192MM in." (11/3/2017)

Who are some of Dynavax Technologies' key competitors?

Who are Dynavax Technologies' key executives?

Dynavax Technologies' management team includes the folowing people:
  • Mr. Eddie Gray, CEO & Director (Age 59)
  • Dr. Dennis A. Carson, Co-Founder & Director (Age 71)
  • Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 66)
  • Mr. David F. Novack, Sr. VP of Operations and Quality (Age 56)
  • Dr. Robert L. Coffman, Chief Scientific Officer and Sr. VP (Age 71)

Has Dynavax Technologies been receiving favorable news coverage?

Media stories about DVAX stock have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dynavax Technologies earned a news sentiment score of 0.16 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.29 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a number of of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (8.13%), BlackRock Inc. (6.21%), Franklin Resources Inc. (4.32%), Federated Investors Inc. PA (3.89%), venBio Select Advisor LLC (2.65%) and Senvest Management LLC (2.46%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Robert Coffman and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Which institutional investors are selling Dynavax Technologies stock?

DVAX stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Millennium Management LLC, Federated Investors Inc. PA, C WorldWide Group Holding A S, Allianz Asset Management GmbH, Senvest Management LLC, Candriam Luxembourg S.C.A. and BlackRock Inc.. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, David Louis Johnson and Robert Coffman. View Insider Buying and Selling for Dynavax Technologies.

Which institutional investors are buying Dynavax Technologies stock?

DVAX stock was acquired by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Franklin Resources Inc., Point72 Asset Management L.P., Chicago Capital LLC, DekaBank Deutsche Girozentrale, UBS Group AG, Fisher Asset Management LLC and Rock Springs Capital Management LP. View Insider Buying and Selling for Dynavax Technologies.

How do I buy shares of Dynavax Technologies?

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dynavax Technologies' stock price today?

One share of DVAX stock can currently be purchased for approximately $16.75.

How big of a company is Dynavax Technologies?

Dynavax Technologies has a market capitalization of $1.06 billion and generates $330,000.00 in revenue each year. The biopharmaceutical company earns $-95,150,000.00 in net income (profit) each year or ($1.73) on an earnings per share basis. Dynavax Technologies employs 170 workers across the globe.

How can I contact Dynavax Technologies?

Dynavax Technologies' mailing address is 2929 SEVENTH STREET SUITE 100, BERKELEY CA, 94710. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]


MarketBeat Community Rating for Dynavax Technologies (DVAX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  516
MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote "Outperform" if you believe DVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Dynavax Technologies (NASDAQ:DVAX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Dynavax Technologies in the last 12 months. Their average twelve-month price target is $27.40, suggesting that the stock has a possible upside of 64.07%. The high price target for DVAX is $30.00 and the low price target for DVAX is $25.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.802.803.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.40$27.40$27.60$28.00
Price Target Upside: 64.07% upside45.36% upside60.47% upside39.65% upside

Dynavax Technologies (NASDAQ:DVAX) Consensus Price Target History

Price Target History for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Cantor FitzgeraldSet Price TargetBuy$27.00HighView Rating Details
5/10/2018JPMorgan ChaseUpgradeNeutral ➝ Overweight$25.00HighView Rating Details
3/9/2018Royal Bank of CanadaReiterated RatingBuy$25.00MediumView Rating Details
2/21/2018CowenReiterated RatingBuy$30.00LowView Rating Details
8/9/2017William BlairReiterated RatingOutperform$30.00HighView Rating Details
9/2/2016S&P Equity ResearchBoost Price Target$11.28 ➝ $16.01N/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Dynavax Technologies (NASDAQ:DVAX) Earnings History and Estimates Chart

Earnings by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ:DVAX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.15)
2019 EPS Consensus Estimate: ($1.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.47)($0.47)($0.47)
Q2 20181($0.59)($0.59)($0.59)
Q3 20181($0.57)($0.57)($0.57)
Q4 20181($0.52)($0.52)($0.52)
Q1 20191($0.44)($0.44)($0.44)
Q2 20191($0.35)($0.35)($0.35)
Q3 20191($0.26)($0.26)($0.26)
Q4 20191($0.17)($0.17)($0.17)

Dynavax Technologies (NASDAQ DVAX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.61)N/AView Earnings Details
5/8/2018Q1 2018($0.49)($0.63)$0.82 million$0.17 millionViewN/AView Earnings Details
3/8/2018Q4 2017($0.11)($0.43)$0.53 million$0.02 millionViewN/AView Earnings Details
11/3/2017Q3 2017($0.53)($0.38)$0.28 million$0.05 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.41)$0.15 million$0.11 millionViewN/AView Earnings Details
5/8/2017Q1 2017($0.60)($0.60)$0.75 million$0.15 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.85)($0.56)$2.90 million$7.30 millionViewN/AView Earnings Details
11/7/2016Q3($0.75)($0.90)$2.44 million$0.20 millionViewN/AView Earnings Details
8/5/2016Q2($0.68)($0.75)$1.58 million$2.65 millionViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.70)$627.00 million$942.00 millionViewN/AView Earnings Details
3/8/2016Q4($0.75)($0.70)$1.15 million$0.69 millionViewN/AView Earnings Details
11/5/2015Q3($0.78)($0.82)$1.65 million$1.20 millionViewN/AView Earnings Details
8/7/2015Q2($1.00)($0.80)$3.05 million$1.55 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.95)($0.97)$1.26 million$0.63 millionViewN/AView Earnings Details
3/5/2015Q4 2014($1.06)($0.85)$2.15 million$2.28 millionViewN/AView Earnings Details
11/5/2014Q314($0.09)($0.11)$2.50 million$2.21 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.09)$2.26 million$3.05 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.06)($0.05)$4.22 million$3.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.07)($0.09)$1.56 million$2.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.10)($0.09)$1.83 million$2.93 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.10)($0.09)$2.91 million$3.40 millionViewN/AView Earnings Details
5/6/2013Q113($0.11)($0.11)$2.40 million$2.10 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.11)$11.40 million$1.80 millionViewN/AView Earnings Details
11/1/2012Q312($0.08)($0.10)$5.00 million$2.90 millionViewN/AView Earnings Details
8/1/2012Q2 2012($1.00)($0.90)ViewN/AView Earnings Details
4/27/2012Q1 2012($0.80)($1.06)ViewN/AView Earnings Details
3/6/2012Q4 2011($0.70)($0.30)ViewN/AView Earnings Details
10/27/2011Q3 2011($1.30)($1.23)ViewN/AView Earnings Details
7/20/2011Q2 2011($1.10)($0.90)ViewN/AView Earnings Details
5/5/2011Q1 2011($1.50)($1.58)ViewN/AView Earnings Details
3/8/2011Q4 2010($1.40)($1.43)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.30)($0.55)ViewN/AView Earnings Details
7/30/2010Q2 2010($1.30)($3.41)ViewN/AView Earnings Details
5/6/2010Q1 2010($1.69)ViewN/AView Earnings Details
3/16/2010Q4 2009($7.31)ViewN/AView Earnings Details
10/22/2009Q3 2009($2.40)($2.37)ViewN/AView Earnings Details
8/4/2009Q2 2009$0.40$1.03ViewN/AView Earnings Details
4/28/2009Q1 2009($0.20)$1.28ViewN/AView Earnings Details
3/2/2009Q4 2008($0.60)$0.78ViewN/AView Earnings Details
11/3/2008Q3 2008($1.10)($1.36)ViewN/AView Earnings Details
8/5/2008Q2 2008($2.40)($1.53)ViewN/AView Earnings Details
4/29/2008Q1 2008($2.30)($3.12)ViewN/AView Earnings Details
2/19/2008Q4 2007($3.40)($3.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Dynavax Technologies (NASDAQ:DVAX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Dynavax Technologies (NASDAQ DVAX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.47%
Institutional Ownership Percentage: 79.38%
Insider Trading History for Dynavax Technologies (NASDAQ:DVAX)
Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies (NASDAQ DVAX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018David F NovackInsiderSell16,109$16.30$262,576.70View SEC Filing  
3/13/2018David F NovackInsiderSell34,214$16.52$565,215.2821,613View SEC Filing  
3/9/2018David F NovackInsiderSell2,121$17.97$38,114.3777,192View SEC Filing  
1/4/2018David Louis JohnsonVPSell3,092$18.60$57,511.207,780View SEC Filing  
12/13/2017Robert CoffmanInsiderSell7,500$18.90$141,750.00View SEC Filing  
1/24/2017Robert JanssenVPBuy6,000$4.04$24,240.0012,048View SEC Filing  
6/28/2016Robert JanssenVPBuy1,452$13.68$19,863.366,048View SEC Filing  
5/20/2016Eddie GrayCEOBuy2,750$15.57$42,817.505,050View SEC Filing  
5/12/2016Robert JanssenVPBuy1,000$15.12$15,120.001,000View SEC Filing  
8/14/2014Eddie GrayCEOBuy25,000$1.49$37,250.00View SEC Filing  
10/30/2013Peggy V PhillipsDirectorBuy93,023$1.08$100,464.84View SEC Filing  
9/14/2012Jennifer LewVPSell18,750$4.53$84,937.50View SEC Filing  
9/13/2012Robert CoffmanVPSell8,000$4.52$36,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Dynavax Technologies (NASDAQ DVAX) News Headlines

Source:
DateHeadline
4 Names to Watch Ahead of This Years Key Cancer-Research Conference4 Names to Watch Ahead of This Year's Key Cancer-Research Conference
finance.yahoo.com - May 19 at 4:44 PM
BidaskClub Upgrades Dynavax Technologies (DVAX) to "Hold"BidaskClub Upgrades Dynavax Technologies (DVAX) to "Hold"
www.americanbankingnews.com - May 18 at 5:13 PM
Dynavax (DVAX) to Present New Data for SD-101 in Combination with KEYTRUDA at ASCODynavax (DVAX) to Present New Data for SD-101 in Combination with KEYTRUDA at ASCO
www.streetinsider.com - May 18 at 10:27 AM
Dynavax Technologies (DVAX) Cut to Hold at ValuEngineDynavax Technologies (DVAX) Cut to Hold at ValuEngine
www.americanbankingnews.com - May 17 at 10:56 PM
Should Dynavax Technologies Corporation’s (NASDAQ:DVAX) Recent Earnings Worry You?Should Dynavax Technologies Corporation’s (NASDAQ:DVAX) Recent Earnings Worry You?
finance.yahoo.com - May 17 at 4:42 PM
Cantor Fitzgerald Analysts Give Dynavax Technologies (DVAX) a $27.00 Price TargetCantor Fitzgerald Analysts Give Dynavax Technologies (DVAX) a $27.00 Price Target
www.americanbankingnews.com - May 17 at 1:53 PM
7 ‘Strong Buy’ Stocks Analysts Are Upgrading Now7 ‘Strong Buy’ Stocks Analysts Are Upgrading Now
finance.yahoo.com - May 15 at 9:40 AM
Dynavax Technologies (DVAX) Rating Increased to Buy at ValuEngineDynavax Technologies (DVAX) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 11 at 8:29 PM
BidaskClub Downgrades Dynavax Technologies (DVAX) to SellBidaskClub Downgrades Dynavax Technologies (DVAX) to Sell
www.americanbankingnews.com - May 11 at 8:05 PM
Dynavax Will Not Be Another SynergyDynavax Will Not Be Another Synergy
seekingalpha.com - May 11 at 10:11 AM
Analysts Issue Forecasts for Dynavax Technologies Q2 2018 Earnings (DVAX)Analysts Issue Forecasts for Dynavax Technologies' Q2 2018 Earnings (DVAX)
www.americanbankingnews.com - May 11 at 9:05 AM
JPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology ConferenceJPMorgan Sees Entry Point In Dynavax Ahead Of June Oncology Conference
finance.yahoo.com - May 10 at 4:44 PM
Dynavax Technologies (DVAX) Upgraded by JPMorgan Chase to OverweightDynavax Technologies (DVAX) Upgraded by JPMorgan Chase to Overweight
www.americanbankingnews.com - May 10 at 4:23 PM
Edited Transcript of DVAX earnings conference call or presentation 8-May-18 8:30pm GMTEdited Transcript of DVAX earnings conference call or presentation 8-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 9:26 AM
BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63
www.reuters.com - May 9 at 4:43 PM
Dynavax Earnings: Excellent Progress On Vaccine Commercialization And Pipeline DevelopmentDynavax Earnings: Excellent Progress On Vaccine Commercialization And Pipeline Development
seekingalpha.com - May 9 at 9:13 AM
Dynavax Technologies (DVAX) CEO Eddie Gray on Q1 2018 Results - Earnings Call TranscriptDynavax Technologies' (DVAX) CEO Eddie Gray on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:13 AM
Dynavax Technologies (DVAX) Announces  Earnings ResultsDynavax Technologies (DVAX) Announces Earnings Results
www.americanbankingnews.com - May 8 at 10:28 PM
Dynavax Technologies (DVAX) Receives "Buy" Rating from Cantor FitzgeraldDynavax Technologies (DVAX) Receives "Buy" Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 8 at 9:15 PM
Dynavax Reports First Quarter 2018 Financial ResultsDynavax Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 4:44 PM
Dynavax Technologies Corporation (NASDAQ:DVAX) Is Expected To BreakevenDynavax Technologies Corporation (NASDAQ:DVAX) Is Expected To Breakeven
finance.yahoo.com - May 7 at 9:47 AM
 Analysts Expect Dynavax Technologies (DVAX) Will Announce Quarterly Sales of $820,000.00 Analysts Expect Dynavax Technologies (DVAX) Will Announce Quarterly Sales of $820,000.00
www.americanbankingnews.com - May 7 at 4:26 AM
Dynavax Technologies (DVAX) Expected to Announce Earnings of -$0.51 Per ShareDynavax Technologies (DVAX) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - May 5 at 9:32 AM
Dynavax to Host First Quarter 2018 Financial Results Conference CallDynavax to Host First Quarter 2018 Financial Results Conference Call
finance.yahoo.com - May 2 at 4:51 PM
Dynavax Technologies (DVAX) Given Consensus Recommendation of "Hold" by AnalystsDynavax Technologies (DVAX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 2 at 1:42 AM
Dynavax Technologies (DVAX) Stock Rating Lowered by ValuEngineDynavax Technologies (DVAX) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 1 at 10:02 AM
Dynavax Technologies (DVAX) Set to Announce Quarterly Earnings on MondayDynavax Technologies (DVAX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - April 30 at 9:21 AM
Dynavax’s HEPLISAV-B ACIP recommendations published in the CDC’s MMWRDynavax’s HEPLISAV-B ACIP recommendations published in the CDC’s MMWR
seekingalpha.com - April 23 at 9:29 AM
Dynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly ReportDynavax’s HEPLISAV-B® ACIP Recommendations Published in the CDC’s Morbidity and Mortality Weekly Report
finance.yahoo.com - April 23 at 9:29 AM
Dynavax Technologies (DVAX) Cut to "Hold" at BidaskClubDynavax Technologies (DVAX) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 22 at 6:46 AM
$820,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter$820,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter
www.americanbankingnews.com - April 20 at 4:25 AM
Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...)Pre-Open Stock Movers 04/16: (ERI) (ALKS) (DVAX) Higher; (CLDX) (ALGT) (NLNK) Lower (more...)
www.streetinsider.com - April 18 at 4:40 PM
-$0.51 EPS Expected for Dynavax Technologies Co. (DVAX) This Quarter-$0.51 EPS Expected for Dynavax Technologies Co. (DVAX) This Quarter
www.americanbankingnews.com - April 18 at 9:35 AM
Dynavax: Positive Results, Market ConfusionDynavax: Positive Results, Market Confusion
seekingalpha.com - April 18 at 9:27 AM
Brokers Issue Forecasts for Dynavax Technologies Co.s Q1 2019 Earnings (DVAX)Brokers Issue Forecasts for Dynavax Technologies Co.'s Q1 2019 Earnings (DVAX)
www.americanbankingnews.com - April 18 at 8:42 AM
Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual MeetingDynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 17 at 9:19 AM
Dynavax Technologies (DVAX) Given a $27.00 Price Target by Cantor Fitzgerald AnalystsDynavax Technologies (DVAX) Given a $27.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - April 16 at 6:30 PM
Investors bullish on early-stage data on Dynavaxs SD-101 + Keytruda in advanced melanoma; shares up 14% premarketInvestors bullish on early-stage data on Dynavax's SD-101 + Keytruda in advanced melanoma; shares up 14% premarket
seekingalpha.com - April 16 at 9:34 AM
Dynavax shares rise 14% on promising cancer conference dataDynavax shares rise 14% on promising cancer conference data
finance.yahoo.com - April 16 at 9:34 AM
Dynavax Technologies (DVAX) Rating Increased to Buy at BidaskClubDynavax Technologies (DVAX) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - April 16 at 7:00 AM
Dynavax Technologies (DVAX) PT Set at $7.00 by Royal Bank of CanadaDynavax Technologies (DVAX) PT Set at $7.00 by Royal Bank of Canada
www.americanbankingnews.com - April 15 at 5:39 PM
Dynavax Technologies (DVAX) Upgraded to "Outperform" by Royal Bank of CanadaDynavax Technologies (DVAX) Upgraded to "Outperform" by Royal Bank of Canada
www.americanbankingnews.com - April 15 at 9:45 AM
Dynavax Technologies (DVAX) Rating Increased to Overweight at JPMorgan ChaseDynavax Technologies (DVAX) Rating Increased to Overweight at JPMorgan Chase
www.americanbankingnews.com - April 15 at 9:43 AM
Investors Buy High Volume of Put Options on Dynavax Technologies (DVAX)Investors Buy High Volume of Put Options on Dynavax Technologies (DVAX)
www.americanbankingnews.com - April 12 at 7:01 AM
Dynavax Technologies (DVAX) "Outperform" Rating Reaffirmed at CowenDynavax Technologies' (DVAX) "Outperform" Rating Reaffirmed at Cowen
www.americanbankingnews.com - April 11 at 5:01 PM
Dynavax Technologies (DVAX) Rating Lowered to Hold at BidaskClubDynavax Technologies (DVAX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - April 10 at 10:24 AM
Dynavax Technologies Co. (DVAX) Receives Consensus Recommendation of "Buy" from BrokeragesDynavax Technologies Co. (DVAX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 7 at 1:29 AM
Watch These April Biotech CatalystsWatch These April Biotech Catalysts
seekingalpha.com - April 3 at 9:10 AM
Dynavax Technologies Co. (DVAX) Expected to Post Earnings of -$0.51 Per ShareDynavax Technologies Co. (DVAX) Expected to Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - April 1 at 7:22 AM
Dynavax Technologies (DVAX) Stock Rating Lowered by BidaskClubDynavax Technologies (DVAX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 28 at 9:49 PM

SEC Filings

Dynavax Technologies (NASDAQ:DVAX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Dynavax Technologies (NASDAQ:DVAX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Dynavax Technologies (NASDAQ DVAX) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.